News

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

  • Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per share, associated with Phase 3 clinical trial provides sufficient upside from today's share price.
    10/03/2022

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

  • Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
    09/30/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Spero Therapeutics, Inc. (SPRO) can hold. Click on Rating Page for detail.

The price of Spero Therapeutics, Inc. (SPRO) is 2.03 and it was updated on 2022-10-06 13:00:25.

Currently Spero Therapeutics, Inc. (SPRO) is in undervalued.

News
    
News

Hot Penny Stocks To Watch As The Stock Market Crash Continues

  • Hot penny stocks to add to your watch list this week. Is it time to buy?
    Mon, Sep. 26, 2022

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

  • The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
    Fri, Sep. 23, 2022

Reddit Penny Stocks to Watch as September Ends

  • Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    Fri, Sep. 23, 2022

Spero's stock jumps 188% after GSK licenses experimental antibiotic

  • Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.
    Thu, Sep. 22, 2022

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

  • Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.
    Thu, Sep. 22, 2022
SEC Filings
SEC Filings

Spero Therapeutics, Inc. (SPRO) - S-8

  • SEC Filings
  • 09/20/2021

Spero Therapeutics, Inc. (SPRO) - D

  • SEC Filings
  • 07/14/2021

Spero Therapeutics, Inc. (SPRO) - S-8

  • SEC Filings
  • 03/11/2021

Spero Therapeutics, Inc. (SPRO) - S-3

  • SEC Filings
  • 03/11/2021

Spero Therapeutics, Inc. (SPRO) - S-8

  • SEC Filings
  • 08/06/2020

Spero Therapeutics, Inc. (SPRO) - S-8

  • SEC Filings
  • 03/19/2020
Press Releases
StockPrice Release
More Headlines
News

Looking for Popular Penny Stocks to Buy? 3 to Watch Now

  • Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?
  • 09/08/2022

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

  • Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.
  • 09/07/2022

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?

  • Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).
  • 09/07/2022

Spero Therapeutics to Present at Upcoming Investor Conference

  • CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:
  • 09/07/2022

Are These Penny Stocks on Your September Buy List?

  • Here's what you need to know about buying penny stocks on September 7th The post Are These Penny Stocks on Your September Buy List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/07/2022

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Senior Clinical Advisor Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 Financial Results Conference Call.
  • 08/11/2022

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

  • Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 08/10/2022

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

  • CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
  • 08/09/2022

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations Ankit Mahadevia - Chief Executive Officer David Melnick - Chief Medical Officer Sath Shukla - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Ram Selvaraju - H.C. Wainwright Kevin DeGeeter - Oppenheimer Elaine Kim - Berenberg Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter of 2022 Financial Results Conference Call.
  • 05/16/2022

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

  • Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 05/16/2022

Spero Therapeutics to Present at Upcoming Investor Conferences

  • CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, which are taking place May 17-18 and May 23-25, respectively. Details for the presentations are as follows:
  • 05/11/2022

Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022

  • CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline.
  • 05/09/2022

SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plunges 50%

  • Spero Therapeutics (SPRO) stock is taking a beating on Tuesday after the biotech company revealed a change in strategic direction. The post SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plunges 50% appeared first on InvestorPlace.
  • 05/03/2022

Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

  • CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022, in Lisbon, Portugal.
  • 04/21/2022

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript
  • 03/31/2022

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

  • Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 03/31/2022

Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?

  • Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 03/29/2022

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022

  • CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.
  • 03/17/2022

FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program

  • The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed.
  • 01/04/2022

Spero (SPRO) Application for UTI Drug Gets Priority Review

  • Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
  • 01/04/2022

Spero Therapeutics to Present at Upcoming Investor Conferences

  • CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.
  • 11/17/2021

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript
  • 11/10/2021

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

  • Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 11/10/2021

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

  • CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an update on its business and pipeline.
  • 11/03/2021

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

  • Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 10/28/2021

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

  • Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board
  • 10/12/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on September 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,900 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 10/01/2021

Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners

  • Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million.  Spero will use the proceeds to prepare for the anticipated launch of tebipenem HBr and support the continued clinical development of SPR720 and SPR206.
  • 09/30/2021

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million

  • Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023
  • 09/30/2021

Spero Therapeutics to Present Data at IDWeek 2021

  • CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero's oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI.
  • 09/16/2021

Spero Therapeutics to Present at Three Upcoming Investor Conferences

  • CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, and the 2021 Cantor Virtual Global Healthcare Conference, taking place virtually September 13 – 15th, 2021, September 20 – 23rd, 2021, and September 27 – 30th, 2021, respectively.
  • 09/07/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on August 31, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,300 shares of its common stock to 7 new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 08/31/2021

Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)

  • Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
  • 08/31/2021

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript
  • 08/07/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on July 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 07/30/2021

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

  • CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 – 14, 2021. Details for the presentation are as follows:
  • 07/07/2021

DuPont De Nemours, Inc Among Today's Trending Stocks

  • Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.
  • 07/06/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on June 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 85,650 shares of its common stock to nine new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 07/02/2021

Why Spero Therapeutics Stock Is Up 15% Today

  • The small biopharma's work has captured the attention of a much bigger player.
  • 07/01/2021

SPRO Stock Price Increases Over 25% Pre-Market: Why It Happened

  • The stock price of Spero Therapeutics, Inc. (Nasdaq: SPRO) increased by over 25% pre-market. This is why it happened.
  • 07/01/2021

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

  • Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties.
  • 06/30/2021

Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206

  • CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero's potentiator platform and is being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. These trials, which are now open for enrollment, include a bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment clinical trial.
  • 06/15/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on May 28, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,000 shares of its common stock to seven new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 05/28/2021

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript

  • Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript
  • 05/09/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on April 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 04/30/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on March 31, 2021 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,050 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 03/31/2021

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript

  • Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript
  • 03/11/2021

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

  • Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 03/11/2021

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

  • Tebipenem HBr advancing towards NDA submission in the second half of 2021
  • 03/11/2021

Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know

  • Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 03/08/2021

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

  • CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline.
  • 03/03/2021

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

  • CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero's investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).
  • 02/05/2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on January 29, 2021 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,300 shares of its common stock to six new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 01/29/2021

Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?

  • Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.
  • 01/26/2021

Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

  • CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587, which is directed to a crystalline formulation of tebipenem HBr, Spero's oral carbapenem in development for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
  • 01/21/2021

Spero: Tebipenem HBr's H2 2021 NDA, SPR720's Phase 2a Data Release And More

  • Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is running three clinical phase therapeutic programs including Tebipenem HBr - Phase 3 [complete] for cUTIs, SPR720 - Phase 2a for NMT-PD, and SPR206 - Phase 1 for MDRi.
  • 01/13/2021

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

  • CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
  • 12/17/2020

Spero Therapeutics Added to the NASDAQ Biotechnology Index

  • CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.
  • 12/16/2020

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

  • CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero's oral antimicrobial agent in development for the treatment of NTM-PD.
  • 12/10/2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on November 30, 2020 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 11/30/2020

Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020

  • CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference taking place December 1 – 3, 2020.
  • 11/30/2020

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript

  • Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
  • 11/07/2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on October 30, 2020 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 11/03/2020

5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)

  • Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in biotech research and investments, which included 15 years working at Mark Lampert's Biotechnology Value Fund, to seek out mispriced small-cap companies in the biotech sector. The fund's assets under management surpassed $500 million as of August 2020.
  • 10/26/2020
Unlock
SPRO Ratings Summary
SPRO Quant Ranking